Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
touchCONGRESS
Start Learning
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
JOURNALS
Start Learning
Dr Elena Crisà on how precision medicine is revolutionalizing haematology: touchHAEMATOLOGY Future Leader 2025
JOURNALS
Start Learning
Dr Esra Gülderen on learning, leadership and lifelong growth: touchHAEMATOLOGY Future Leader 2025
JOURNALS
Start Learning
Positive phase III VERIFY study results for rusfertide in polycythemia vera
touchCONGRESS
Start Learning
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
CE/CME ACCREDITED
JOURNALS
Start Learning
#ASH24: Discover the 2024 late-breaking abstracts
touchPANEL DISCUSSION
Start Learning
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
CE/CME ACCREDITED
touchMDT
Start Learning
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
View
BVd compared to DVd in RRMM: The DREAMM-7 trial
View
Blinatumomab advances outcomes in paediatric B-cell acute lymphoblastic leukemia: phase 3 AALL1731 trial findings
View
Collaboration in chronic ITP: Improving quality of life and patient outcomes
View
Greatest Hits of 2024
View
Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group
View
Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
View
Combination therapy in myelofibrosis: John Mascarenhas on the IMpactMF trial
View
EHA 2025: The countdown is on!
View
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup